Compare Stocks: QNTM, ATRA, GANX, and IBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.54 -2.6%	$9.67	$3.92 ▼ $19.15	$76.95M	0.12	794,277 shs	32,524 shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$76.77M	0.19	808,855 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.60	$0.56 ▼ $3.82	$69.55M	1.31	1.25 million shs	301,644 shs
QNTM Quantum Biopharma	$2.90 +1.0%	$3.80	$2.07 ▼ $31.91	$18.56M	0.45	290,366 shs	91,153 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+2.57%	+12.29%	-24.72%	+70.29%	-22.53%
GANX Gain Therapeutics	+0.57%	+1.73%	-7.85%	-7.85%	+19.73%
IBIO iBio	+2.82%	+5.04%	-13.10%	-17.51%	+145,999,900.00%
QNTM Quantum Biopharma	-5.90%	-4.33%	-18.23%	-45.64%	-89.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.54 -2.6%	$9.67	$3.92 ▼ $19.15	$76.95M	0.12	794,277 shs	32,524 shs
GANX Gain Therapeutics	$1.80 +2.3%	$1.79	$1.45 ▼ $4.34	$76.77M	0.19	808,855 shs	293,835 shs
IBIO iBio	$1.40 -4.1%	$1.60	$0.56 ▼ $3.82	$69.55M	1.31	1.25 million shs	301,644 shs
QNTM Quantum Biopharma	$2.90 +1.0%	$3.80	$2.07 ▼ $31.91	$18.56M	0.45	290,366 shs	91,153 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+2.57%	+12.29%	-24.72%	+70.29%	-22.53%
GANX Gain Therapeutics	+0.57%	+1.73%	-7.85%	-7.85%	+19.73%
IBIO iBio	+2.82%	+5.04%	-13.10%	-17.51%	+145,999,900.00%
QNTM Quantum Biopharma	-5.90%	-4.33%	-18.23%	-45.64%	-89.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.00	Hold	$9.50	11.24% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	316.67% Upside
IBIO iBio	3.13	Buy	$5.00	257.14% Upside
QNTM Quantum Biopharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNTM, ATRA, GANX, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
7/1/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
6/30/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
6/9/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/8/2026	IBIO iBio	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/5/2026	IBIO iBio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$120.77M	0.64	$4.85 per share	1.76	($5.34) per share	-1.60
GANX Gain Therapeutics	$50K	1,535.40	N/A	N/A	$0.48 per share	3.75
IBIO iBio	$300K	231.84	N/A	N/A	$0.90 per share	1.56
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$1.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	$32.69M	-$0.67	N/A	6.10	N/A	-40.91%	-79.12%	-35.29%	8/10/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.58	N/A	N/A	N/A	N/A	-201.44%	-136.24%	8/11/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)
QNTM Quantum Biopharma	-$26.17M	-$8.25	N/A	N/A	N/A	N/A	-941.54%	-224.41%	8/6/2026 (Estimated)

Latest QNTM, ATRA, GANX, and IBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.14	N/A	N/A	N/A	$0.03 million	N/A
8/10/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	N/A	N/A	N/A	$0.55 million	N/A
8/6/2026	N/A	QNTM Quantum Biopharma	-$0.4116	N/A	N/A	N/A	N/A	N/A
5/12/2026	Q1 2026	ATRA Atara Biotherapeutics	-$0.3295	-$0.29	+$0.0395	-$0.29	$2.90 million	$0.52 million
5/12/2026	Q3 2026	IBIO iBio	-$0.06	-$0.07	-$0.01	-$0.06	$0.02 million	N/A
5/11/2026	Q1 2026	GANX Gain Therapeutics	-$0.13	-$0.13	N/A	-$0.13	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	2.16	2.16
GANX Gain Therapeutics	0.02	4.69	4.69
IBIO iBio	N/A	11.88	11.88
QNTM Quantum Biopharma	N/A	0.63	0.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
GANX Gain Therapeutics	11.97%
IBIO iBio	7.90%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	41.20%
GANX Gain Therapeutics	4.15%
IBIO iBio	2.75%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	9.01 million	5.30 million	No Data
GANX Gain Therapeutics	20	42.65 million	40.88 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A
QNTM Quantum Biopharma	N/A	6.40 million	5.85 million	N/A

QNTM, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

August 3 at 6:06 PM | markets.businessinsider.com

Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results

August 3 at 6:06 PM | finance.yahoo.com

Quantum Biopharma (NASDAQ:QNTM) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | americanbankingnews.com

Quantum Biopharma (QNTM) to Post Earnings on Thursday

July 30, 2026 | americanbankingnews.com

Quantum BioPharma Announces Closing of Debt Settlement

July 29, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

July 29, 2026 | finance.yahoo.com

Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions

July 22, 2026 | finance.yahoo.com

Quantum BioPharma Announces Intention to Settle Debt

July 20, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy

July 15, 2026 | finance.yahoo.com

Why Quantum BioPharma (QNTM) Is 'One to Watch'

July 10, 2026 | finance.yahoo.com

Quantum BioPharma Provides Corporate Update

July 7, 2026 | globenewswire.com

Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

July 2, 2026 | finance.yahoo.com

Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

June 29, 2026 | finance.yahoo.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study

June 29, 2026 | markets.businessinsider.com

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

June 26, 2026 | globenewswire.com

The Quest to Repair What Multiple Sclerosis Takes Away

June 25, 2026 | markets.businessinsider.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

June 25, 2026 | globenewswire.com

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 23, 2026 | markets.businessinsider.com

Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 23, 2026 | finance.yahoo.com

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

June 23, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.54 -0.23 (-2.62%)

As of 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Gain Therapeutics NASDAQ:GANX

$1.80 +0.04 (+2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 0.00 (0.00%)

As of 04:15 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

iBio NASDAQ:IBIO

$1.40 -0.06 (-4.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 0.00 (-0.29%)

As of 04:51 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Quantum Biopharma NASDAQ:QNTM

$2.90 +0.03 (+1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$2.84 -0.06 (-2.07%)

As of 04:32 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, ATRA, GANX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, ATRA, GANX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNTM, ATRA, GANX, and IBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNTM, ATRA, GANX, and IBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNTM, ATRA, GANX, and IBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM, ATRA, GANX, and IBIO Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

Gain Therapeutics NASDAQ:GANX

iBio NASDAQ:IBIO

Quantum Biopharma NASDAQ:QNTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools